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Background: The impact of rituximab on health-related quality of life (HRQoL) in primary central nervous system
lymphoma patients is not well known. We determined the impact of rituximab added to standard high-dose
methotrexate-based treatment on HRQoL in patients in a large randomised trial.
Patients and methods: Patients from a large phase III trial (HOVON 105/ALLG NHL 24), randomly assigned to receive
standard chemotherapy with or without rituximab and followed by 30 Gy whole brain radiotherapy (WBRT) in patients
60 years, completed the EORTC QLQ-C30 and QLQ-BN20 questionnaires before and during treatment, and up to
24 months of follow-up or progression. Differences between treatment arms over time in global health status, role
functioning, social functioning, fatigue, and motor dysfunction were assessed. Differences 10 points were deemed
clinically relevant. The effect of WBRT on HRQoL was analysed in irradiated patients.
Results: A total of 160/175 patients eligible for the HRQoL study completed at least one questionnaire and were
included. Over time, scores improved statistically significantly and were clinically relevant in both arms. Between
arms, there were no differences on any scale (range: 3.8 to þ4.0). Scores on all scales were improved to a
clinically relevant extent at 12 and 24 months compared with baseline in both arms, except for fatigue and motor
dysfunction at 12 months (7.4 and 8.8, respectively). In irradiated patients (n ¼ 59), scores in all preselected
scales, except motor dysfunction, remained stable up to 24 months compared with shortly after WBRT, overall
mean difference ranging between 0.02 and 4.570.
Conclusion: Compared with baseline, treatment resulted in improved HRQoL scores.The addition of rituximab to standard
chemotherapy did not impact HRQoL over time. WBRT did not result in deterioration of HRQoL in the first 2 years.
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Volume xxx - Issue xxx - 2020decades, the incidence rate has increased, mainly amongst
patients >60 years old, and prognosis has improved
significantly.1,2 This prolonged survival has largely been
determined by improvements in treatment.1,3
In systemic diffuse large B-cell lymphoma patients, the
addition of rituximab, a chimeric monoclonal antibody
targeting the CD20 cell surface protein, to standard
treatment has been shown to improve progression-free
survival and overall survival.4,5 Since most PCNSL are
diffuse large B-cell lymphoma (DLBCL), it has beenhttps://doi.org/10.1016/j.annonc.2020.04.014 1
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Table 1. Baseline sociodemographic and clinical characteristics of the





Sex, n (% male) 56 (62) 41 (48)
Age (years), median (IQR) 61 (55e66) 61 (55e67)
WHO performance score, n (%)
WHO 0 19 (21) 23 (27)
WHO 1 46 (51) 42 (49)
WHO 2 15 (17) 12 (14)
WHO 3 10 (11) 8 (9)
Comorbidities active at baseline, n (% 2) 54 (60) 51 (60)
Solitary lesion, n (%) 46 (51) 44 (52)
Missing (NA) 10 (11) 4 (5)
Bilateral involvement, n (%) 33 (37) 33 (39)
Missing (NA) 10 (11) 4 (5)
Deep structures involved, n (%) 55 (61) 57 (67)
Study drug exposure
HD cytarabine (Ara-C), n (%) 82 (91) 76 (89)
WBRT, n (%) 33 (37) 34 (40)
Radiation boost given, n (%) 15 (17) 23 (27)
Intrathecal treatment given, n (%) 8 (9) 8 (9)
MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP,
rituximab with methotrexate, tenoposide, BCNU (carmustine), and prednisolone; NA,
not applicable in case of no brain lesion(s); IQR, interquartile range; HD, high-dose;
WBRT, whole brain radiotherapy; WHO, World Health Organization.
M. van der Meulen et al. Annals of Oncologyhypothesised that the addition of rituximab to standard
treatment with high-dose methotrexate (HD-MTX)-based
chemotherapy could also improve survival in PCNSL pa-
tients. The HOVON 105/ALLG NHL 24, a large interna-
tional multicenter phase III randomised, controlled trial
(RCT), investigated the addition of rituximab to standard
HD-MTX-based chemotherapy, followed by 30 Gy whole
brain radiotherapy (WBRT) in patients aged 60 years.
The primary end point, the 1-year event-free survival,
was not improved by rituximab [HD-MTX, tenoposide,
BCNU (carmustine), and prednisolone without (MBVP)
versus with rituximab (R-MBVP): 49% versus 52%,
P ¼ 0.99].6
When introducing a new treatment, information on both
survival and the patients’ functioning and well-being should
be taken into account. Combined, these outcomes deter-
mine the ‘net clinical benefit’ of a treatment strategy. By
combining both sources of information, clinicians and pa-
tients are better able to make well-informed decisions
concerning which treatment is most suitable for an indi-
vidual patient.
In this study, we describe the health-related quality of life
(HRQoL) trajectories in one of the largest RCTs in PCNSL
patients and determined whether the addition of rituximab
to standard therapy had an impact on HRQoL. Second, we
aimed to determine the effect of a lower dose WBRT on
HRQoL in this patient population.Figure 1. Consolidated Standards of Reporting Trials diagram representing the co
treatment arms.
FU, months of follow-up after end of treatment; HRQoL, health-related quality of life;
rituximab with methotrexate, tenoposide, BCNU (carmustine), and prednisolone; WB
*In those who had WBRT only.
Volume xxx - Issue xxx - 2020METHODS
Study design and patient population
In the HOVON 105/ALLG NHL 24 study, 199 immunocom-
petent patients aged 18e70 years, with a newly diagnosed,
CD20-positive B-cell PCNSL were included from Dutch,
Australian, and New Zealand hospitals between 2010 and
2016.6 Patients were randomised between two courses of
HD-MTX, tenoposide, BCNU, and prednisolone without
(MBVP) or with rituximab (R-MBVP). Irrespective of treat-
ment arm, this induction regimen was followed by con-
solidative HD-cytarabine chemotherapy in responding
patients, and in patients 60 years old, 30 Gy WBRT was
subsequently added. An integrated boost to the tumor-bed
of 10 Gy was given to patients who only achieved partial
response.7 (Immuno-)chemotherapy treatment duration
was 2.5e3.5 months and WBRT was administered in 1
month. Further details on the study design and treatment
have been published previously.6 The study was approved
by the ethics committees of all participating centres. All
participants who signed informed consent for the RCT and
for participating in the HRQoL study were eligible for in-
clusion in this analysis.
HRQoL
HRQoL was one of the prespecified secondary outcomes.
HRQoL was assessed using the European Organisation for
Research and Treatment of Cancer (EORTC) core quality of
life questionnaire (QLQ-C30),8 and the brain cancer module
(QLQ-BN20).9,10 The QLQ-C30 comprises five functional
scales (physical, role, emotional, social, and cognitive
functioning), three symptom scales (fatigue, pain, and
nausea and vomiting), a global health status (GH)/QoL scale,
and six single items assessing additional symptoms (dys-
pnea, sleep disturbance, appetite loss, constipation, and
diarrhoea) and perceived financial difficulties. The QLQ-
BN20 module includes 20 items, comprising four scales
(visual disorders, motor dysfunction, communication deficit,
and future uncertainty), and seven disease- or toxicity-
related symptoms (headache, seizures, drowsiness, hair
loss, itchy skin, weakness of the legs, and bladder control).
According to protocol, patients had to complete the
questionnaires before starting chemotherapy, after
completion of all chemotherapy, after completion of
radiotherapy (if given), and 3, 6, 12, and 24 months after
completion of protocol treatment. The assessment of
HRQoL was stopped when a relapse or progression
occurred, or when a patient wanted to withdraw from
participation in either the RCT or HRQoL sub-study. Only
questionnaires that were completed within a prespecified
time window (see supplementary Methods, available atmpliance with HRQoL assessments during follow-up, separately for the two
MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP,
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Figure 2. Health-related quality of life scores over time for the five primary scales [(i) global health status; (ii) role functioning; (iii) social functioning; (iv) fatigue;
(v) motor dysfunction], separately for both treatment arms in the total study population, based on results of the linear mixed model analyses.
Estimated marginal means for each evaluation point by treatment arm, where the vertical bars represent 95% confidence interval of the group mean.
BL, baseline; CT, chemotherapy; FU, follow-up; MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP, rituximab with methotrexate,
tenoposide, BCNU (carmustine), and prednisolone; RT, radiotherapy.
Annals of Oncology M. van der Meulen et al.Annals of Oncology online.) for each evaluation point were
included in the statistical analysis.Statistical analysis
Calculation of HRQoL scores. Following the EORTC pro-
cedures, raw item scores were converted to a linear scale4 https://doi.org/10.1016/j.annonc.2020.04.014ranging from 0 to 100.11 A difference of 10 points on each
HRQoL scale/item was defined as clinically relevant.12 Based
on clinical relevance for PCNSL patients, these five scales
were selected for primary analysis: three functional scales
[GH, role functioning (RF), and social functioning (SF), with
higher scores representing better functioning], and two
symptom scales [fatigue and motor dysfunction (MD), withVolume xxx - Issue xxx - 2020
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Figure 3. Individual changes in health-related quality of life from baseline to 12 months and 24 months of follow-up.
FA, fatigue; GH, global health status/quality of life; MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; MD, motor dysfunction; R-MBVP, rituximab
with methotrexate, tenoposide, BCNU (carmustine), and prednisolone; RF, role functioning; SF, social functioning.
M. van der Meulen et al. Annals of Oncologyhigh scores representing worse functioning]. Results of the
primary analysis (i.e. scores over time assessed with linear
mixed models in the five predetermined scales), were cor-
rected for multiple testing. The remaining scales and items
were analysed on an exploratory basis. All analyses were
conducted with Stata, version 15, and a P value <0.05 was
considered to be statistically significant.
Descriptive statistics. Patients eligible for the HOVON
105/ALLG NHL 24 study who received less than two courses
of (R-)MBVP, or who did not give consent for the HRQoL
sub-study, were excluded from the analysis. We carried out
a non-response analysis to assess possible imbalances be-
tween those who gave consent for the HRQoL sub-study
and those who did not with respect to sociodemographic
and clinical characteristics.
Differences were tested using a chi-square test for cate-
gorical data and ManneWhitney U or independent t-test for
continuous data, depending on the distribution of the data.
Normality was determined with the KolmogoroveSmirnov
test. In addition, for each time point, the compliance was
evaluated, defined as the number of completed question-
naires divided by the number of questionnaires expected at
that time point. We defined a completed questionnaire as a
returned form from which at least a score of one of the
predetermined primary scales could be derived.
HRQoL scores over time. At group level, mean changes
from baseline were calculated and plotted for those pa-
tients who filled in the questionnaire at baseline and at
least at one follow-up point. Differences between arms atVolume xxx - Issue xxx - 202012 and 24 months of follow-up were assessed with an in-
dependent t-test. A linear mixed model, which allows in-
clusion of all patients, with fixed effects for treatment arm,
time (i.e. evaluation moments) as a categorical covariate,
and their interaction, was used to assess whether there is a
difference in the HRQoL scores over time between the
treatment arms. For each scale, the most suitable covari-
ance structure was chosen to estimate the impact of the
treatment on HRQoL over time.
At the individual patient level, changes in HRQoL be-
tween baseline and both 12 and 24 months of follow-up
were calculated for those patients to whom the question-
naires at these time points were available. Patients were
categorised as deteriorated, stable, or improved, based on a
change of 10 points. Differences between treatment arms
were assessed with the chi-square statistic.
Deterioration-free survival and time to deterioration.
Deterioration-free survival was defined as a deterioration of
10 points on a scale/item compared with baseline without
an improvement of 10 points at the subsequent HRQoL
assessment, or progressive disease (PD) or death in the
absence of definite deterioration before the next assess-
ment. Time to deterioration was defined similarly as
deterioration-free survival, only excluding PD as an event.13
PD was defined according to the international PCNSL
response criteria.7 Magnetic resonance images were cen-
trally reviewed; the centrally scored progression data were
used for these analyses. Questionnaires filled in at the time
of, or after centrally scored PD were excluded. Kaplane
Meier curves were generated for both deterioration-freehttps://doi.org/10.1016/j.annonc.2020.04.014 5
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Figure 4. Deterioration-free survival and time to deterioration for Global health status (GH), separately for the treatment arms.
MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP, rituximab with methotrexate, tenoposide, BCNU (carmustine), and prednisolone.
Annals of Oncology M. van der Meulen et al.survival and time to deterioration, and 95% confidence
intervals were calculated using the Greenwood formula.
Impact of WBRT. The impact of radiation on HRQoL was
evaluated in a subgroup of thosewho receivedWBRT (n¼ 59).
The mean changes from the ‘after WBRT’ time point onwards
were calculated and linearmixedmodel analyses were carried
out to analyse HRQoL scores over the post-WBRT period.
RESULTS
Patients
Of the 199 patients included in the HOVON 105/ALLG NHL
24 trial, 193 (97%) gave informed consent for HRQoL6 https://doi.org/10.1016/j.annonc.2020.04.014assessment. Eighteen patients were excluded because they
did not complete two courses of (R-)MBVP, resulting in 175/
199 (88%) eligible patients for the HRQoL analysis. Of these
175 patients included in the HRQoL analysis, 160 completed
at least one questionnaire. Compliance of HRQoL evaluation
was 60% at each time point, except ‘after WBRT’ in the
MBVP arm (46%) (Figure 1).
In the population participating in the HRQoL analysis,
patients in the treatment arms were well balanced with
respect to clinical and sociodemographic features and study
drug exposure. Those included in this HRQoL analysis had a
median age of 61 years (interquartile range 55e66 years),
and 74% had a WHO performance score <2, which is similarVolume xxx - Issue xxx - 2020
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Figure 5. Health-related quality of life scores from post-whole brain radiotherapy up to 24 months follow-up for the preselected scales [(i) global health status; (ii)
role functioning; (iii) social functioning; (iv) fatigue; (v) motor dysfunction], separately for the treatment arms, in the irradiated patients only (n [ 59).
Estimated marginal means for each evaluation point by treatment arm, where the vertical bars represent 95% confidence interval of the group mean.
FU, follow-up; MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP, rituximab with methotrexate, tenoposide, BCNU (carmustine), and
prednisolone; RT, radiotherapy.
M. van der Meulen et al. Annals of Oncologyto the total trial population6 (Table 1). The non-response
analysis showed that there were no significant differences
with respect to baseline characteristics between those who
gave consent for the HRQoL sub-study and those who did
not (supplementary Table S1, available at Annals of
Oncology online.). Baseline HRQoL scores for all scales and
items for both treatment arms are summarised inVolume xxx - Issue xxx - 2020supplementary Table S2, available at Annals of Oncology
online.HRQoL scores over time
In all selected primary scales, the mean change from
baseline, assessed in those who filled in the questionnaireshttps://doi.org/10.1016/j.annonc.2020.04.014 7
Annals of Oncology M. van der Meulen et al.at baseline and at least once thereafter, showed a statisti-
cally significant (all P < 0.002) and clinically relevant
improvement in both arms after the end of treatment (i.e.
‘after chemotherapy’ or ‘after WBRT’), when compared with
baseline, except for fatigue. Fatigue improved more slowly;
clinically relevant improvement was not reached before 3
months after treatment. The differences in scores between
the arms at 12 and 24 months of follow-up were not sta-
tistically significant or clinically relevant for any of the
scales. Only fatigue at 12 months after treatment was
clinically relevant worse in the R-MBVP arm, but this was
not statistically significant; R-MBVP versus MBVP: 18.1
versus 7.4 (P ¼ 0.677). For most exploratory scales and
items, similar patterns were observed. See supplementary
Figure S1 and Table S3, available at Annals of Oncology
online, for the graphs presenting the mean change from
baseline over time for all scales/items and the actual mean
difference at each time point, respectively.
In a next step, HRQoL scores over time were assessed with
linear mixed models, allowing inclusion of all patients as
these models impute data at all time points (Figure 2). These
analyses showed that the mean HRQoL score improved
significantly in all primary selected scales over time in both
arms (P < 0.001), confirming the previous analyses. We did
not find any statistically significant or clinically relevant
differences over time between the treatment arms for any of
the preselected scales: overall mean difference over time in
MBVP versus R-MBVP: GH¼0.074 (P¼ 0.981), RF¼ 2.160
(P ¼ 0.635), SF ¼ 0.531 (P ¼ 0.902), fatigue ¼ 3.350
(P ¼ 0.378), and MD ¼ 2.139 points (P ¼ 0.511). The results
of the linear mixed models show that the largest improve-
ments in scores were between baseline and ‘end of treat-
ment’, thereafter, the scores gradually improved further, but
to a lesser extent. GH remained stable from end of treatment
until 24 months after treatment. Exploratory scales and
items are shown in supplementary Figure S2, available at
Annals of Oncology online.
Assessing the change from baseline scores at the indi-
vidual level, in all patients who filled in the questionnaires
at baseline and at least at one point thereafter, we
observed in a large proportion of patients in both arms an
improvement to a clinically relevant extent in HRQoL scores
on all primary scales. At 12 months of follow-up, 46%e78%
of the patients had improved scores compared with base-
line, and these percentages were between 53% and 82% at
24 months of follow-up (Figure 3). There were no significant
differences between the arms. See supplementary Table S4
available at Annals of Oncology online, for the exact number
of patients who improved, remained stable, or deteriorated
in both the preselected and exploratory HRQoL scales and
items.Deterioration-free survival and time to deterioration
The addition of rituximab to MBVP-chemotherapy did not
result in a statistically significant longer deterioration-free
survival or time to deterioration in any of the preselected
scales. The median deterioration-free survival in RF was not8 https://doi.org/10.1016/j.annonc.2020.04.014reached. The median deterioration-free survival in MBVP
versus R-MBVP was for GH: 19.6 versus not reached, SF:
19.6 versus 22.7, fatigue: 6.7 versus 6.7, and MD: 4.2 versus
3.8 months. For time to deterioration, the median was not
reached in GH, RF, and SF. The median time to deterioration
in MBVP versus R-MBVP in fatigue was 10.2 versus 7.5 and
MD: 4.7 versus 3.8 months. See Figure 4 for the
deterioration-free survival and time to deterioration for GH
and supplementary Figure S3 and Table S5, available at
Annals of Oncology online, for the remaining primary
scales/items.Impact of WBRT
Seventy patients received WBRT, of whom 59 participated in
the HRQoL evaluation. The linear mixed model analysis
(which allows inclusion of all 59 patients) showed no statis-
tically significant change over time after WBRT up to 24
months, except for a deterioration in MD (P ¼ 0.048). There
were no significant differences between treatment arms:
overall mean difference MBVP versus R-MBVP GH ¼ 1.951
(P¼ 0.694), RF¼ 4.570 (P¼ 0.542), SF¼ 3.007 (P¼ 0.677),
fatigue ¼ 1.887 (P ¼ 0.776), and MD ¼ 0.020 (P ¼ 0.997),
see Figure 5.
The change in HRQoL from WBRT onwards was only
determined in those patients who were irradiated and who
filled in the questionnaires at the evaluation ‘after WBRT’
and at least at one of the follow-up evaluations (n ¼ 34).
This subpopulation was comparable to the total irradiated
population (data not shown).We observed an improvement
(>10 points) in RF in both arms (P ¼ 0.002), from 62.1 after
WBRT to 78.8 at 24 months follow-up in the R-MBVP arm,
and from 65.3 to 77.5 in the MBVP arm. Scores in the other
preselected scales remained stable in both treatment arms
(see supplementary Figure S4, available at Annals of
Oncology online, for the preselected scales).
DISCUSSION
In the HOVON 105/ALLG NHL 24 trial, the addition of rit-
uximab to standard chemotherapy in adult PCNSL patients
did not prolong event-free survival (EFS) or progression-free
survival (PFS). In this HRQoL analysis in 160 patients (80% of
total study population), we showed that the addition of
rituximab did not improve or deteriorate the patients’
functioning and well-being, either. We did, however,
observe that antitumour treatment resulted in improve-
ments in HRQoL, which were statistically significant and
clinically relevant, but did not differ between patients
treated with or without rituximab.
The largest improvements in HRQoL were observed
directly after treatment (i.e. after induction chemotherapy
with or without rituximab and after consolidation with
WBRT, if given). Thereafter, HRQoL scores remained rela-
tively stable or improved more slowly, but gradually over
time. Other non-randomised studies investigating the effect
of chemotherapy and/or chemotherapy with rituximab on
HRQoL have described a similar pattern: an initial
improvement after treatment, followed by stabilisation ofVolume xxx - Issue xxx - 2020
M. van der Meulen et al. Annals of OncologyHRQoL scores for up to 3 years of follow-up.14e16 Two small
studies (in which 12/52 and 16/33 of the patients partici-
pated in the HRQoL sub-study) even showed an ongoing
improvement in HRQoL scores (as measured with the
Functional Assessment of Cancer Therapy-Brain; FACT-Br)
up to 1217 and 24 months of follow-up.18 Clinical rele-
vance of this change was, however, not defined. Never-
theless, this pattern suggests that HRQoL in PSCNL patients
is mainly compromised by the lymphoma itself rather than
by the treatment, and that treating the tumour improves
patient-reported HRQoL.
Mean baseline HRQoL scores in our cohort are much
lower (20 points) than in the general population,19 and
also lower (10 points) than in patients with brain me-
tastases, low-grade glioma, and glioblastoma.20e22 HRQoL
scores in our population improved significantly over time, to
levels of the general population for some scales, whereas
scores in low- and high-grade glioma patients typically
remain stable up to 24 months of follow-up.21,22 The non-
significant differences between treatment arms in
deterioration-free survival and time to deterioration for any
of the HRQoL scales suggest that treatment itself did not
cause a major deterioration in HRQoL.
WBRT as consolidation treatment is under debate
because of its presumed negative effect on neurocognitive
functioning and subsequently on HRQoL.23 Surprisingly, we
found that the HRQoL scores of those patients receiving
radiation remained stable for up to 2 years of follow-up
after WBRT, suggesting that the WBRT dose (30 Gy) used
in this study does not compromise HRQoL in patients up to
60 years old in the period covered by this analysis, despite
the fact that 17% of the patients in the MBVP arm and 27%
in the R-MBVP arm also received an integrated boost of 10
Gy to the tumour bed. A possible explanation for the stable
HRQoL in our cohort after WBRT may be that the 24 month
period in our study is too short to develop radiation-
induced damage detectable with HRQoL instruments, or
that the lower radiation dose is less detrimental. Our
findings are supported by a study by Correa et al.24 in which
patients treated with R-MPV followed by low-dose WBRT
(23.4 Gy) also remained stable in their HRQoL scores, even
up to 5 years of follow-up. Only a small number of patients
could be analysed in our subanalysis and results should
therefore be interpreted with caution. In addition, patients
who received WBRT could not be compared directly to
those who did not receive WBRT because of the age dif-
ference between the irradiated and non-irradiated patients.
Thus, although our results cannot be generalised and
follow-up is still short, our results do challenge the negative
role of a relatively low-dose WBRT in this younger
subpopulation.
The strengths of our study are the size and standardised
treatment of the population studied, the use of validated
measures for brain cancer patients, and the fact that the
majority of this trial population participated in the HRQoL
sub-study. Although the compliance at most time points
was relatively high (60%), which is sufficient for robust
longitudinal analyses with linear mixed models, the resultsVolume xxx - Issue xxx - 2020should be interpreted with some caution. This is emphas-
ised by the fact that the actual number of patients who
filled in the questionnaires was relatively low at 12 and 24
months of follow-up (n ¼ 74 and n ¼ 53, respectively) due
to progression or death, and patients filling out the ques-
tionnaires might have a higher level of functioning and well-
being than those not filling out the questionnaires. Also,
HRQoL was not systematically assessed at the moment of
and beyond progression, hampering information on the
impact of progression on HRQoL in this patient population.
Another limitation is possible selection bias, because we
analysed (subgroups of) a trial population and results may
therefore not be generalisable to all patients. However,
most patients in the trial also participated in the HRQoL
sub-study and only those who did not tolerate two com-
plete courses of (R-)MBVP were excluded. Lastly, the
impact of treatment on neurocognition is important in this
patient population, and will be described in a separate
publication.
In conclusion, HRQoL scores improved after treatment
but were not impacted by the addition of rituximab to
standard chemotherapy in adult PCNSL patients. Secondly,
treatment with 30 Gy WBRT did not reduce HRQoL in the
first 2 years after treatment in patients up to 60 years old.
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